(UroToday.com) Dr. Piet Ost discussed results of a pooled analysis of prospective trials assessing metastasis-directed therapy for oligorecurrent prostate cancer at the 2021 EAU’s annual meeting metastatic prostate cancer session. To date, prospective data for metastasis-directed therapy for oligorecurrent prostate cancer have been limited to single arm or small phase 2 randomized studies. The objective of this study was to conduct an individual patient data meta-analysis to characterize the safety and clinical benefit of metastasis-directed therapy in oligorecurrent prostate cancer.